RN
Cartesian Therapeutics, Inc.
RNAC · NASDAQ
$8.08 +0.25% (+$0.02)
1M -19.68%
Market Cap $237.4M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 160.73x
P/E N/A
EV/FFO N/A
Growth
0 /100
Declining Rev. growth 70.66%
EPS growth N/A
Book val. growth N/A
Profitability
0 /100
Weak Gross margin 766.42%
FCF margin 5,291.54%
Net margin 10,422.50%
Quality
0 /100
Poor ROIC 30.78%
Asset turnover 0.00x
ROA 48.31%
Debt
43 /100
Moderate Current ratio 7.48x
Int. coverage -188.07x
Debt/Equity N/A
Stability
26 /100
Unstable Beta 0.62x
Profitable years 0
Rev. volatility 77.97%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o RNAC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carsten Brunn
Employees
75
Headquarters
Frederick
Nadchodzące wydarzenia
05 LIS
Earnings
Upcoming earnings report